LMP1 reversibely increases the secretion of CD63-positive sEVs, furthermore, the knockdown of CD63 in cells could cause the reduction of LMP1 in sEVs [46], suggesting that CD63 may be associated with LMP1 sorting into sEVs, which supplies novel therapeutic targets to treat the EBV-associated cancers. The gene discussed is PDLIM7; the disease is cancer.